PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast

Latest Episodes:

Anita H. Clayton, MD - Recent Advances and Novel Options in Depression: Reviewing the Evidence for GABA-Modulating Neuroactive Steroids for Major Depressive Disorder Feb 15, 2022

Show notes

Go online to PeerView.com/TTU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry discusses the evidence for the use of GABA-modulating neuroactive steroids for major depressive disorder. Upon completion of this CE activity, participants will be able to: Summarize the evidence supporting a role for GABAergic dysfunction and altered neuroactive steroid signaling in major depressive disorder (MDD), Recognize the burden of MDD and the impact of delayed or suboptimal treatment on patient outcomes, Evaluate recent safety and efficacy data related to emerging treatment options for MDD, recognizing potential implications for the future treatment landscape.

Steven Brem, MD - A New Wave of Progress in Glioblastoma: Expert Guidance on Delivering Modern Personalized Care With Tumor Treating Fields and Novel Systemic Approaches Jan 26, 2022

Show notes

Go online to PeerView.com/EWB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How do your colleagues incorporate the latest research and guideline recommendations into the clinical management of patients with glioblastoma multiforme (GBM)? With a median overall survival of only 15 months, GBM has long presented a challenge to the multidisciplinary management team. To maximize patient survival and QOL, clinicians who treat patients with this complex, diverse, fast-growing, and aggressive brain tumor must be prepared to quickly create personalized management plans that incorporate several new modalities, including tumor treating fields (TTFields) and efficacious systemic therapies, as well as clinical trial–based options. In a new event from PeerView and the American Brain Tumor Association (ABTA), an expert panel will review the latest efficacy and safety data on multimodal GBM treatments, along with a clear rationale for selecting guideline-recommended treatments and strategies for incorporating these advances into clinical practice. This case-based activity has been designed to help clinicians hone their informed decision-making skills and personalize management plans and for the benefit of patients with GBM in a variety of settings. Upon completion of this CE activity, participants will be able to: Describe the biologic rationale and latest clinical evidence for the use of guideline-recommended treatment strategies, such as TTFields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent GBM, Identify patients with GBM who may benefit from participation in a clinical trial, and assess the applications of emerging approaches based on available data on their efficacy and safety, Develop personalized management plans for patients with newly diagnosed and recurrent GBM, including within the context of clinical trials, based on the current clinical evidence, guideline recommendations, and patient needs and preferences.

Lenard A. Adler, MD / Oren Mason, MD - Overcoming Challenges in the Recognition and Management of Adult ADHD in Primary Care: Optimizing Outcomes to Reduce Disease Burden and Improve Quality of Life Jan 11, 2022

Show notes

Go online to PeerView.com/CQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in attention-deficit/hyperactivity disorder (ADHD) discuss overcoming challenges in the recognition and management of adult ADHD in primary care. Upon completion of this CE activity, participants will be able to: Evaluate the association between attention-deficit/hyperactivity disorder (ADHD) symptoms and functional impairment in adulthood, Utilize evidence-based tools to identify and diagnose adult ADHD, Engage in shared decision-making to optimize ADHD treatment selection and management considering the latest clinical evidence as well as the patient’s ADHD symptoms, psychiatric and medical comorbidities, and individual preferences.

Erik P. Sulman, MD, PhD - Implementing Synergistic Multimodal Approaches With Tumor Treating Fields to Extend Survival in Aggressive Cancers Dec 08, 2021

Show notes

Go online to PeerView.com/QNS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel medical technologies have revolutionized the therapeutic management of difficult-to-treat cancers. In particular, tumor treating fields (TTFields) therapy, which is a state-of-the-art, noninvasive modality that harnesses low intensity alternating electric fields to selectively disrupt tumor cell division and migration, has demonstrated clear benefits in terms of clinical efficacy and minimal toxicity in solid tumors. Approved for the therapeutic management of recurrent and newly diagnosed glioblastoma multiforme (GBM) as well as unresectable, previously untreated malignant pleural mesothelioma (MPM), TTFields therapy in combination with other conventional cancer treatments is being explored in a number of ongoing clinical trials in patients with a range of solid tumors, including lung, pancreatic, gastric, liver, and ovarian cancers. This CME-accredited activity features a review of the latest advancements in cancer technology, along with expert insights and case discussions on the optimal integration and use of recently validated locoregional therapies, such as TTFields, in the clinic. The expert panel will also discuss key safety and efficacy data from recent pivotal clinical trials studying multimodal treatment strategies in GBM, MPM, and other solid tumor types. Upon completion of this CE activity, participants will be able to: Describe the mechanistic rationale and clinical evidence for validated locoregional therapies, such as tumor treating fields (TTFields), for glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Appraise new clinical evidence on investigational multimodal strategies with synergistic mechanisms of action (eg, TTFields in combination with systemic therapy, radiotherapy, or other modalities) across a range of solid tumor types, including lung, pancreatic, gastric, liver, and ovarian cancers, Integrate novel locoregional therapies into the therapeutic management of appropriately selected patients with GBM, MPM, or other solid tumors, including via clinical trial enrollment, Implement team-based strategies to minimize and manage adverse events associated with novel therapeutic modalities in patients with solid tumors.

Benjamin M. Greenberg, MD, MHS & Professor Anthony Traboulsee, MD - Bruton Tyrosine Kinase Inhibitors for MS: Progress in the Development of an Emerging Therapeutic Approach Dec 08, 2021

Show notes

Go online to PeerView.com/NXB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Growing appreciation of the importance of B-cell–targeted therapies in multiple sclerosis (MS) management has spurred research into the potential role that Bruton tyrosine kinase (BTK) inhibitors may play in MS management. In this activity, based on a recent live satellite symposium, expert faculty will put BTK inhibitors into context, starting with the expanding understanding of the inflammatory and neurodegenerative processes of MS, the roles of B cells, microglia, and T cells, and how the ongoing investigations of BTK inhibitors as possible MS treatments build upon the successes of B-cell–targeted therapies. They will also review the evidence related to current clinical trials and engage learners in a case-based discussion exploring how BTK inhibitors might someday be deployed to address unmet needs of individuals with MS. Upon completion of this CE activity, participants will be able to: Recognize characteristics and evidence related to the role of BTK inhibitors in addressing MS pathophysiology, Compare characteristics of BTK inhibitors with other B-cell–targeted therapies, Evaluate available data on the efficacy, safety, and tolerability of BTK inhibitors in the context of addressing the treatment needs of patients with MS.

Bruce Cree, MD, PhD, MAS - Exploring the Convergence of Advances in S1P Receptor Modulation With Progress in Understanding Brain Atrophy and Cognition Measures in Multiple Sclerosis Nov 22, 2021

Show notes

Go online to PeerView.com/FUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, experts in neurology explore the mechanisms of action of S1PR modulators approved for the treatment of multiple sclerosis (MS), highlighting the similarities and differences among treatment options and reviewing the efficacy and safety data for these therapies and their potential effects on markers of treatment response or disease progression (eg, brain atrophy, neurofilament protein levels, cognitive test results). The burden, assessment, and management of cognitive impairment in MS, which occurs in over 50% of people with MS and can greatly affect patients’ functioning and quality of life, is also examined in this activity. The expert faculty also present and discuss patient case scenarios, through which they explore best practices in the care of patients with varied disease presentations and clinical contexts. Upon completion of this CE activity, participants will be able to: Describe the mechanisms of action for S1PR modulators approved for the treatment of MS in the context of disease pathophysiology, Recognize the therapeutic effects of S1PR modulators approved for the treatment of MS, including efficacy, safety, and tolerability, and the potential impact on emerging disease state markers (eg, brain atrophy, neurofilament protein, cognition), Use S1PR modulators appropriately, according to current recommendations and evidence, to meet treatment needs of individuals with MS.

Professor Dame Pamela J. Shaw - On the Cusp of a New Targeted Treatment Era in ALS: Exploring the Emerging Therapeutic Landscape Nov 03, 2021

Show notes

Go online to PeerView.com/RQP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses emerging treatment options for patients with amyotrophic lateral sclerosis. Upon completion of this CE activity, participants will be able to: Evaluate the mechanisms of action, efficacy, and safety of emerging ALS therapies, Identify the potential impact of emerging therapies on genetic testing and treatment guidelines in ALS, Discuss opportunities with patients to participate in clinical trials.